New research links popular asthma drug Singulair to serious mental health issues
Briefly

Research indicates that the asthma drug Singulair (montelukast) may be linked to serious mental health problems, affecting the psychiatric functioning of some patients.
After significant reports of adverse neuropsychiatric effects associated with Singulair, the FDA added a 'black box' warning to highlight its serious mental health risks.
Read at Fast Company
[
|
]